Abstract

On November 10, 2010, the FDA approved the growth hormone-releasing factor analogue tesamorelin (Egrifta) for the treatment of visceral fat

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call